

## SEQUENCE LISTING

<110> Glaxo Group Limited. <1 $\!$ 20> Antibodies to CD23, derivatives thereof, and their therapeutic uses. <130% PG3433 <140> &A 2,328,606 <141> 1\( 99-05-07 <150> PCTXGB99/01434 <151> 1999<del>\</del>05-07 <150> GB 9809839.5 <151> 1998-05-09 <160> 53 <170> PatentIn Ver <210> 1 <211> 415 <212> DNA <213> Mus musculus <220> <221> CDS <222> (3)..(413) <400> 1 aa get tta cag tta etc age aca çag gae etc ace atg gat ttt ggg 47 Ala Leu Gln Leu Leu Ser Thr Gin Asp Leu Thr Met Asp Phe Gly ctg att ttt ttt att gtt ctt tta aaa ggg gtc cag/agt gaa gtg aag 95 Leu Ile Phe Phe Ile Val Leu Leu Lys Gly Val Gln Ser Glu Val Lys 20 ctt gag gag tct gga gga tcc atg aaa 143 Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys ctc tcc tgt gta gcc tct gga ttt act ttc agt ggc tac tgg atg tct 191 Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Gly Tyr Trp Met Ser 50 tgg gtc cgc cag tct cca gag aag ggg ctt gag tgg g $\hbar$ t gct gaa att 239 Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile 65 aga ttg aaa tct gat aat tat gca aca cat tat gcg gag tct gtg aaa 287 Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser Val Lys 80 90 ggg aag ttc acc atc tca aga gat gat tcc aaa agt cgt ctc tak ctg 335 Gly Lys Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg Leu Tyr\Leu 105 caa atg aac agc tta aga gct gaa gac agt gga gtt tat tac tgt aca Gln Met Asn Ser Leu Arg Ala Glu Asp Ser Gly Val Tyr Tyr Cys Thr

115 120 125

gat ttc ata gac tgg ggc caa ggg aca cta gt Asp Phe Ile Asp Trp Gly Gln Gly Thr Leu 130 135	415
<210> 2 <211> 437 <212> DNA <213> Mus musculus	
<220> <221> CDS <222> (3)(437)	
<pre>&lt;400&gt; 2 aa gct tta cag tta ctc agc aca cag gac ctc acc atg agg ttc tct Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Arg Phe Ser</pre>	47
gtt cag ttt ctg ggg gtg ctt atg ttc tgg atc tct gga gtc agt ggg Val Gln Phe Leu Gly Val Leu Met Phe Trp Ile Ser Gly Val Ser Gly 20 25 30	95
gat att gtg ata acc cag gat gaa ctc tcc aat cct gtc act tct gga Asp Ile Val Ile Thr Gln Asp Glu Leu Ser Asn Pro Val Thr Ser Gly 35 40 45	143
gaa toa gtt too ato too tgo agg tot agt aag agt oto otg tat aag Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys 50 55 60	191
gat ggg aag aca tac ttg aat tgg ttt ctg cag aga cca gga caa tct Asp Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser 65 70 75	239
cct cag ctc ctg atg tat ttg atg tcc acc cgt gca tca gga gtc tca Pro Gln Leu Leu Met Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Ser 80 85 90 95	287
gac cgg ttt agt ggc agt ggg tca ggc aca gat ttc acc ctg gaa atc Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile 100 105 110	335
agt aga gtg aag gct gag gat gtg gtg tat tac tgt caa caa ctt Ser Arg Val Lys Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu 115 120 125	383
gta gag tat cca ttc acg ttc ggc tcg ggg aca aag ttg gaa ata aaa Val Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 130 135 140	431
cgt acg Arg Thr 145	437
<210> 3 <211> 16 <212> PRT <213> Mus musculus	

```
<400> 3
Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn
                  5
                                      10
<210> 4
<211> 48
<212> DNA
<213> Mus musculus
<220>
<221> CDS
<222> (1)..(48)
<400> 4
cgc tcg agt aag agt ctc ctg tat aag gat ggg aag aca tac ttg aat
                                                                  48
Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn
<210> 5
<211> 7
<212> PRT
<213> Mus musculus
<400> 5
Leu Met Ser Thr Arg Ala Ser
<210> 6
<211> 21
<212> DNA
<213> Mus musculus
<220>
<221> CDS
<222> (1)..(21)
<400> 6
ttg atg tcc acc cgg gca tca
                                                                    21
Leu Met Ser Thr Arg Ala Ser
<210> 7
<211> 9
<212> PRT
<213> Mus musculus
Gln Gln Leu Val Glu Tyr Pro Phe Thr
 1
<210> 8
<211> 27
<212> DNA
<213> Mus musculus
<220>
<221> CDS
<222> (1)..(27)
```

1)

```
<400> 8
caa cag ctg gta gag tat cca ttc acg
                                                                     27
Gln Gln Leu Val Glu Tyr Pro Phe Thr
<210> 9
<211> 5
<212> PRT
<213> Mus musculus
<400> 9
Gly Tyr Trp Met Ser
 1
<210> 10
<211> 15
<212> DNA
<213> Mus musculus
<220>
<221> CDS
<222> (1)..(15)
<400> 10
ggc tac tgg atg tcc
                                                                    15
Gly Tyr Trp Met Ser
 1
<210> 11
<211> 19
<212> PRT
<213> Mus musculus
<400> 11
Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser
  1
                  5
                                      10
Val Lys Gly
<210> 12
<211> 57
<212> DNA
<213> Mus musculus
<220>
<221> CDS
<222> (1)..(57)
<400> 12
gaa att aga ttg aaa tct gat aat tat gca aca cat tat gcg gag tct
                                                                    48
Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser
                                      10
gtg aag ggg
                                                                    57
Val Lys Gly
<210> 13
```

```
<400> 13
000
<210> 14
<400> 14
000
<210> 15
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      sequence
<400> 15
Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
                                      10
Val His Ser
<210> 16
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      sequence
<400> 16
Met Ala Trp Val Trp Thr Leu Leu Phe Leu Met Ala Ala Ala Gln Ser
  1
                  5
Ala Gln Ala
<210> 17
<211> 348
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: Humanised
      anti-CD23 antibody light chain variable region
<220>
<221> CDS
<222> (1)..(348)
<400> 17
gat att gtg atg act cag tct cca ctc tcc ctg ccc gtc acc cct gga
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
                                      10
                                                          15
gag ccg gcc tcc atc tcc tgt cgc tcg agt aag agt ctc ctg tat aag
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys
```

20 25 30

	Gly															144
cca Pro	cag Gln 50	ctc Leu	ctg Leu	atc Ile	tat Tyr	ttg Leu 55	atg Met	tcc Ser	acc Thr	cgg Arg	gca Ala 60	tca Ser	ggg Gly	gtc Val	cct Pro	192
	agg Arg															240
	aga Arg															288
gta Val	gag Glu	tat Tyr	cca Pro 100	ttc Phe	acg Thr	ttc Phe	ggc Gly	caa Gln 105	ggg Gly	acc Thr	aag Lys	gtg Val	gag Glu 110	atc Ile	aaa Lys	336
_	acg Thr		_													348
<21 <21	0> 18 1> 13 2> DN 3> An	335 NA	lcial	L Sed	quenc	ce										
<22	)>															
	3> D∈ ar				E Art ibody								n.			
<221 <221 <221	ar	nti-C	D23	anti									n.			
<222 <222 <222 <400 gag	ar )> L> CI	nti-( )S .)( } cag	D23 (1335 ctg	anti  ) gtg	ibody gag	y hea	aaa ava o	chair	yaı ggc	riab]	le re	egior	ccc	ggg Gly 15	glà āāā	48
<223 <223 <223 <400 gag Glu 1	ar )> L> CI 2> (1 )> 18 gtg	nti-C	CD23 C1335 Ctg Leu Ctc	anti  gtg Val 5 tcc	gag Glu tgt	tct Ser gca	ggg Gly gct	gga Gly agc	ggc Gly 10	ttg Leu	gta Val	aag Lys ttc	ccc Pro	Gly 15	Gly	<b>4</b> 8 96
<22: <22: <22: <400 gag Glu 1 tcc Ser	ar )> 1> CI 2> (1) )> 18   gtg   Val   ctt	os .)( cag Gln aga Arg	ctg Leu ctc Leu 20	gtg Val 5 tcc Ser	gag Glu tgt Cys	tct Ser gca Ala	ggg Gly gct Ala	gga Gly agc Ser 25	ggc Gly 10 gga Gly	ttg Leu ttc Phe	gta Val act Thr	aag Lys ttc Phe	ccc Pro agt Ser 30	Gly 15 ggc Gly	Gly tac Tyr	
<22: <22: <22: <400 gag Glu 1 tcc ser tgg Trp	ar  >>	os .)( } cag Gln aga Arg tcc Ser 35	ctg Leu ctc Leu 20 tgg Trp	gtg Val 5 tcc Ser gtc Val	gag Glu tgt Cys cgc Arg	tct Ser gca Ala cag Gln	ggg Gly gct Ala gct Ala 40	gga Gly agc Ser 25 cca Pro	ggc Gly 10 gga Gly ggg Gly	ttg Leu ttc Phe aag Lys	gta Val act Thr ggg Gly	aag Lys ttc Phe ctc Leu 45 cat	ccc Pro agt Ser 30 gag Glu	Gly 15 ggc Gly tgg Trp	tac Tyr gtt Val	96
<22: <22: <22: <400 gag Glu 1 tcc ser tgg Trp gct Ala	ar  )> 1> CI 2> (1)  )> 18 gtg  Val  ctt Leu  atg Met  gaa Glu	os cag Gln aga Arg tcc Ser 35 att	ctg Leu ctc Leu 20 tgg Trp aga Arg	gtg Val 5 tcc Ser gtc Val ttg Leu	gag Glu tgt Cys cgc Arg aaa Lys	tct Ser gca Ala cag Gln tct Ser 55	ggg Gly gct Ala 40 gat Asp	gga Gly agc Ser 25 cca Pro aat Asn	ggc Gly 10 gga Gly ggg Gly tat Tyr	ttg Leu ttc Phe aag Lys gca Ala	gta Val act Thr ggg Gly aca Thr 60	aag Lys ttc Phe ctc Leu 45 cat His	ccc Pro agt Ser 30 gag Glu tat Tyr	Gly 15 ggc Gly tgg Trp gcg Ala	tac Tyr gtt Val gag Glu	96

	Leu	Tyr	Leu	Gln	Met 85		Ser	Leu	Lys	Thr 90		Asp	Thr	Ala	Val 95	Tyr	
	tac Tyr	tgt Cys	aca Thr	gat Asp 100	ttc Phe	ata Ile	gac Asp	tgg Trp	ggc Gly 105	cag Gln	gga Gly	aca Thr	cta Leu	gtc Val 110	acc Thr	gtc Val	336
·	tcc Ser	tca Ser	gcc Ala 115	Ser	acc Thr	aag Lys	ggc Gly	cca Pro 120	tcg Ser	gtc Val	ttc Phe	ccc Pro	ctg Leu 125	gca Ala	ccc Pro	tcc Ser	384
	tcc Ser	aag Lys 130	agc Ser	acc Thr	tct Ser	GJA aaa	ggc Gly 135	aca Thr	gcg Ala	gcc Ala	ctg Leu	ggc Gly 140	tgc Cys	ctg Leu	gtc Val	aag Lys	432
	gac Asp 145	tac Tyr	ttc Phe	ccc Pro	gaa Glu	ccg Pro 150	gtg Val	acg Thr	gtg Val	tcg Ser	tgg Trp 155	aac Asn	tca Ser	ggc Gly	gcc Ala	ctg Leu 160	480
	acc Thr	agc Ser	ggc Gly	gtg Val	cac His 165	acc Thr	ttc Phe	ccg Pro	gct Ala	gtc Val 170	cta Leu	cag Gln	tcc Ser	tca Ser	gga Gly 175	ctc Leu	528
	tac Tyr	tcc Ser	ctc Leu	agc Ser 180	agc Ser	gtg Val	gtg Val	acc Thr	gtg Val 185	ccc Pro	tcc Ser	agc Ser	agc Ser	ttg Leu 190	ggc Gly	acc Thr	576
	cag Gln	acc Thr	tac Tyr 195	atc Ile	tgc Cys	aac Asn	gtg Val	aat Asn 200	cac His	aag Lys	ccc Pro	agc Ser	aac Asn 205	acc Thr	aag Lys	gtg Val	624
	gac Asp	aag Lys 210	aaa Lys	gtg Val	gag Glu	ccc Pro	aaa Lys 215	tct Ser	tgt Cys	gac Asp	aaa Lys	act Thr 220	cac His	aca Thr	tgc Cys	cca Pro	672
	ccg Pro 225	tgc Cys	cca Pro	gca Ala	cct Pro	gaa Glu 230	ctc Leu	gcg Ala	Gly	gca Ala	ccg Pro 235	tca Ser	gtc Val	ttc Phe	ctc Leu	ttc Phe 240	720
	ccc Pro	cca Pro	aaa Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	acc Thr	Pro	gag Glu 255	Val	768
	aca Thr	tgc Cys	gtg Val	gtg Val 260	gtg Val	gac Asp	gtg Val	agc Ser	cac His 265	gaa Glu	gac Asp	cct Pro	gag Glu	gtc Val 270	aag Lys	ttc Phe	816
	aac Asn	tgg Trp	tac Tyr 275	gtg Val	gac Asp	ggc Gly	gtg Val	gag Glu 280	gtg Val	cat His	aat Asn	gcc Ala	aag Lys 285	aca Thr	aag Lys	ccg Pro	864
	Arg	gag Glu 290	gag Glu	cag Gln	tac Tyr	aac Asn	agc Ser 295	acg Thr	tac Tyr	cgt Arg	gtg Val	gtc Val 300	agc Ser	gtc Val	ctc Leu	acc Thr	912
	Val 305	Leu	His	Gln	Asp	Trp 310	Leu	Asn	Gly	Lys	Glu 315	Tyr	aag Lys	Cys	Lys	Val 320	960
	tcc Ser	aac Asn	aaa Lys	gcc Ala	ctc Leu	cca Pro	gcc Ala	ccc Pro	atc Ile	gag Glu	aaa Lys	acc Thr	atc Ile	tcc Ser	aaa Lys	gcc Ala	1008

• ,

325 330 335

aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg 340 345 350	1056									
gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365	1104									
ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 380	1152									
gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400	1200									
ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag cag Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln $405$ $410$ $415$	1248									
ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430	1296									
tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa tga Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440	1335									
<210> 19 <211> 57 <212> DNA <213> Artificial Sequence										
<220> <223> Description of Artificial Sequence: Oligo										
<400> 19 gatgaagett tacagttaet cageacaeag gaeeteaeea tggattttgg getgatt	57									
<210> 20	3,									
<211> 25 <212> DNA										
<2213> Artificial Sequence	<213> Artificial Sequence									
<223> Description of Artificial Sequence: Oligo										
<400> 20 gatggactag tgtcccttgg cccca										
<210> 21 <211> 57 <212> DNA <213> Artificial Sequence										
<220> <223> Description of Artificial Sequence: Oligo										

```
<400> 21
gatgaagett tacagttact cagcacacag gacctcacca tgaggttctc tgttcag
                                                                    57
<210> 22
<211> 28
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: Oligo
<400> 22
gatgcgtacg tytkatytcc avcttkgt
                                                                    28
<210> 23
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Oligo
<400> 23
gatcaagctt ctctacagtt actgagcaca
                                                                    30
<210> 24
<211> 63
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Oligo
<400> 24
aatcaagtat gtcttcccat ccttatacag gagactctta ctcgagcgac aggagatgga 60
<210> 25
<211> 63
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: Oligo
<400> 25
cgctcgagta agagtctcct gtataaggat gggaagacat acttgaattg gtacctgcag 60
aag
                                                                    63
<210> 26
<211> 36
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Oligo
<400> 26
tgatgcccgg gtggacatca aatagatcag gagctg
                                                                    36
<210> 27
```

```
<211> 36
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: Oligo
<400> 27
ttgatgtcca cccgggcatc aggggtccct gacagg
                                                                    36
<210> 28
<211> 84
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Oligo
<400> 28
agccacctga cgtttgatct ccaccttggt cccttggccg aacgtgaatg gatactctac 60
cagctgttga cagtaataaa cccc
<210> 29
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Oligo
<400> 29
acacgaaget teaceatgge ttgggtgtgg acettgetat teetgatgge ggeegeecaa 60
<210> 30
<211> 66
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Oligo
<400> 30
ctttaccaag cetececeag actecaceag etgeacetet gettgggeac tttgggegge 60
<210> 31
<211> 60
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: Oligo
<400> 31
ttggtaaagc ccggggggtc ccttagactc tcctgtgcag ctagcggatt cactttcagt 60
<210> 32
<211> 60
<212> DNA
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence: Oligo
<400> 32
coccttocot ggagootggo ggacocagga catocagtag coactgaaag tgaatcogot 60
<210> 33
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Oligo
qqqaaqqqqc tcqaqtqqqt tqctqaaatt agattqaaat ctqataatta tqcaacacat 60
<210> 34
<211> 60
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: Oligo
<400> 34
atcatctctt gagatggtga atttcccctt cacagactcc gcataatgtg ttgcataatt 60
<210> 35
<211> 66
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Oligo
<400> 35
atctcaagag atgattcaaa atctagactg tatctgcaaa tgaacagcct gaaaaccgag 60
gacaca
                                                                    66
<210> 36
<211> 69
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Oligo
<400> 36
ggtgactagt gttccctggc cccagtctat gaaatctgta cagtaataca cggctgtgtc 60
ctcggtttt
<210> 37
<211> 48
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Oligo
<400> 37
```

gctgc	teett ttaagetttg gggteaagge teactagte	ca cagtetee	4 8
<210> <211>			
<212> <213>	DNA Artificial Sequence		
<220> <223>	Description of Artificial Sequence:	Oligo	
<400> tgacg	38 gtgcc ceegegagtt cagg		2
<210> <211>			
<211>			
<213>	Artificial Sequence		
<220>			
<223>	Description of Artificial Sequence:	Oligo	
<400>			_
cctgaa	acteg egggggeace gtea		24
<210>			
<211>			
<212>	Artificial Sequence		
	THE CITE OF A CONTROL OF A CONT		
<220>	Description of Artificial Sequence:	Oligo	
(220)	bescription of intelligial bequence.	01190	
<400>			~ ~
aageti	ccgt cgaattcatt tacccggaga cag		33
<210>	41		
<211>			
<212>	DNA Artificial Sequence		
\215/	Altificial Sequence		
<220>	Description of Artificial Sequence:	Primer	
	-	TITMOI	
<400> actagt	41 ccgac atgaagtttc cttctcaact tctgctc		37
<210>	42		
<211>			
<212>	PRT Artificial Sequence		
	Interfrontal bequence		
<220>	Paraminting of Publish 1.2.5		
<223>	Description of Artificial Sequence: sequence	Synthetic	
<400>	42		
	ys Leu Glu Ile Lys Arg Thr		
1	5		

· .

```
<210> 43
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      sequence
<400> 43
Thr Lys Val Glu Ile Lys Arg Thr
                  5
<210> 44
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      sequence
<400> 44
Thr Lys Leu Glu Ile Arg Arg Thr
  1
                  5
<210> 45
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      sequence
<400> 45
Thr Lys Val Glu Ile Arg Arg Thr
<210> 46
<211> 415
<212> DNA
<213> Mus musculus
<400> 46
actagtgtcc cttggcccca gtctatgaaa tctgtacagt aataaactcc actgtcttca 60
gctcttaagc tgttcatttg caggtagaga cgacttttgg aatcatctct tgagatggtg 120
aacttccctt tcacagactc cgcataatgt gttgcataat tatcagattt caatctaatt 180
tcagcaaccc actcaagccc cttctctgga gactggcgga cccaagacat ccagtagcca 240
ctgaaagtaa atccagaggc tacacaggag agtttcatgg atcctccagg ttgcaccaag 300
cctcctccag actcctcaag cttcacttca ctctggaccc cttttaaaag aacaataaaa 360
aaaatcagcc caaaatccat ggtgaggtcc tgtgtgctga gtaactgtaa agctt
                                                                    415
<210> 47
<211> 437
<212> DNA
<213> Mus musculus
```

```
<400> 47
cgtacgtttt atttccaact ttgtccccga gccgaacgtg aatggatact ctacaagttg 60
ttgacagtaa tacacacca catcctcagc cttcactcta ctgatttcca gggtgaaatc 120
tgtgcctgac ccactgccac taaaccggtc tgagactcct gatgcacggg tggacatcaa 180
atacatcagg agctgaggag attgtcctgg tctctgcaga aaccaattca agtatgtctt 240
cccatcctta tacaggagac tcttactaga cctgcaggag atggaaactg attctccaga 300
agtgacagga ttggagagtt catcctgggt tatcacaata tccccactga ctccaqagat 360
ccagaacata agcaccccca gaaactgaac agagaacctc atggtgaggt cctgtgtgct 420
gagtaactgt aaagctt
                                                                   437
<210> 48
<211> 348
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Humanised
      anti-CD23 antibody light chain variable region
<400> 48
agccaccgta cgtttgatct ccaccttggt cccttggccg aacgtgaatg gatactctac 60
cagctgttga cagtaataaa ccccaacatc ctcagcctcc actctgctga ttttcagtgt 120
aaaatctgtg cctgatccac tgccactgaa cctgtcaggg acccctgatg cccgggtgga 180
catcaaatag atcaggagct gtggagactg ccctggcttc tgcaggtacc aattcaagta 240
tgtcttccca tccttataca ggagactctt actcgagcga caggagatgg aggccggctc 300
tccaggggtg acgggcaggg agagtggaga ctgagtcatc acaatatc
                                                                  348
<210> 49
<211> 1335
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Humanised
      anti-CD23 antibody heavy chain variable region
<400> 49
teatttacce ggagacaggg agaggetett etgegtgtag tggttgtqca qageeteatg 60
catcacggag catgagaaga cgttcccctg ctgccacctg ctcttgtcca cgqtgaqctt 120
gctgtagagg aagaaggagc cgtcggagtc cagcacggga qqcqtqqtct tqtaqttqtt 180
ctccggctgc ccattgctct cccactccac ggcgatgtcg ctgggataga agcctttgac 240
caggcaggtc aggctgacct ggttcttggt cagctcatcc cgggatgggg gcagggtqta 300
cacctgtggt tctcggggct qccctttgqc tttggagatg gttttctcga tgggggctgg 360
gagggetttg ttggagacet tgcacttgta etcettgeca ttcagecagt cetggtgcag 420
gacggtgagg acgctgacca cacggtacgt gctgttgtac tgctcctccc gcggctttgt 480
cttqqcatta tqcacctcca cqccgtccac gtaccagttq aacttgacct cagggtcttc 540
gtggctcacg tccaccacca cgcatgtgac ctcaggggtc cgggagatca tgagggtgtc 600
cttgggtttt ggggggaaga ggaagactga cggtgccccc gcgagttcag gtgctgggca 660
cggtgggcat gtgtgagttt tgtcacaaga tttgggctcc actttcttgt ccaccttggt 720
gttgctgggc ttgtgattca cgttgcagat gtaggtctgg gtgcccaagc tgctggaggg 780
cacggtcacc acgctgctga gggagtagag tcctgaggac tgtaggacag ccgggaaggt 840
gtgcacgccg ctggtcaggg cgcctgagtt ccacgacacc gtcaccggtt cggggaagta 900
gtccttgacc aggcagccca gggccgctgt gcccccagag gtgctcttgg aggagggtgc 960
cagggggaag accgatgggc ccttggtgga ggctgaggag acggtgacta gtgttccctg 1020
gccccagtct atgaaatctg tacagtaata cacggctgtg tcctcggttt tcaggctgtt 1080
catttgcaga tacagtctag attttgaatc atctcttgag atggtgaatt tccccttcac 1140
agacteegea taatgtgttg cataattate agattteaat etaattteag caacceacte 1200
gagccccttc cctggagcct ggcggaccca ggacatccag tagccactga aagtgaatcc 1260
gctagctgca caggagagtc taagggaccc cccgggcttt accaagcctc ccccagactc 1320
caccagetge acete
                                                                  1335
```

```
<210> 50
```

<211> 137

<212> PRT

<213> Mus musculus

<400> 50

Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Asp Phe Gly Leu 1 5 10 15

Ile Phe Phe Ile Val Leu Leu Lys Gly Val Gln Ser Glu Val Lys Leu 20 25 30

Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu 35 40 45

Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Gly Tyr Trp Met Ser Trp 50 55 60

Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg 65 70 75 80

Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser Val Lys Gly
85 90 95

Lys Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg Leu Tyr Leu Gln 100 105 110

Met Asn Ser Leu Arg Ala Glu Asp Ser Gly Val Tyr Tyr Cys Thr Asp 115 120 125

Phe Ile Asp Trp Gly Gln Gly Thr Leu 130 135

<210> 51

<211> 145

<212> PRT

<213> Mus musculus

<400> 51

Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Arg Phe Ser Val 1 5 10 15

Gln Phe Leu Gly Val Leu Met Phe Trp Ile Ser Gly Val Ser Gly Asp 20 25 30

Ile Val Ile Thr Gln Asp Glu Leu Ser Asn Pro Val Thr Ser Gly Glu
35 40 45

Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp
50 55 60

Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser Pro 65 70 75 80

Gln Leu Leu Met Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Ser Asp 85 90 95

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile Ser 100 105 110

Arg Val Lys Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu Val

115 120 125

Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg 130 135 140

Thr 145

<210> 52

<211> 116

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Humanised
 anti-CD23 antibody light chain variable region

<400> 52

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys 20 25 30

Asp Gly Lys Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45

Pro Gln Leu Leu Ile Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Pro 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu 85 90 95

Val Glu Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110

Arg Thr Val Ala 115

<210> 53

<211> 444

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Humanised
 anti-CD23 antibody heavy chain variable region.

<400> 53

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr 20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

Ala Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60

Ser Val Lys Gly Lys Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg

٠, ٠, .,

70 75 80

65 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Asp Phe Ile Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser 115 120 Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 135 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu 150 Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val 200 Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Ala Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 250 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 310 315 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 330 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg 345 Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 360 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 375

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser

390

385

. . .

400

395

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 405 410 415

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440

71 - 6